Jessica Katharine Dyson (Jessica K Dyson, Jessica Dyson)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 9

Top Topics

High Performance Liquid Chromatography

Cardiovascular Risk Factors

Metabolic Syndrome

Top Venues

Alimentary pharmacology & therapeutics

Digestive diseases and sciences

Hepatology (Baltimore, Md.)

This page only lists publications with an associated author ORCID identifier.

Publications

David E J Jones, Ulrich H W Beuers, Alan Bonder, Marco Carbone, Emma L Culver, Jessica Katharine Dyson, Robert G Gish, Bettina E Hansen, Gideon M Hirschfield, Rebecca Jones, Kris Kowdley, Andreas E Kremer, Keith D Lindor, Marlyn J Mayo, George Mells, James Neuberger, Martin Prince, Mark G Swain, Atsushi Tanaka, Douglas Thorburn, Michael Trauner, Palak J Trivedi, Martin Weltman, Andrew D Yeoman, Cynthia Levy
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here? Hepatology (Baltimore, Md.) (2024)
Laura Martinez-Gili, Alexandros Pechlivanis, Julie Anne Kathryn McDonald, Sofina Begum, Jonathan Badrock, Jessica Katharine Dyson, Rebecca Jones, Gideon M Hirschfield, Stephen D Ryder, Richard Sandford, Simon Rushbrook, Douglas Thorburn, Simon D Taylor-Robinson, Mary M E Crossey, Julian R Marchesi, George Mells, Elaine Holmes, David Jones
Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis. Gut microbes 15 (1) (2023)
Laura Martinez-Gili, Alexandros Pechlivanis, Julie Anne Kathryn McDonald, Sofina Begum, Jonathan Badrock, Jessica Katharine Dyson, Rebecca Jones, Gideon M Hirschfield, Stephen D Ryder, Richard Sandford, Simon Rushbrook, Douglas Thorburn, Simon D Taylor-Robinson, Mary M E Crossey, Julian R Marchesi, George Mells, Elaine Holmes, David Jones
Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis. Gut microbes 15 (1) (2023)
Laura Martinez-Gili, Alexandros Pechlivanis, Julie Anne Kathryn McDonald, Sofina Begum, Jonathan Badrock, Jessica Katharine Dyson, Rebecca Jones, Gideon M Hirschfield, Stephen D Ryder, Richard Sandford, Simon Rushbrook, Douglas Thorburn, Simon D Taylor-Robinson, Mary M E Crossey, Julian R Marchesi, George Mells, Elaine Holmes, David Jones
Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis. Gut microbes 15 (1) (2023)
Geraldine Carroll, Jessica Katharine Dyson
Editorial: autoimmune hepatitis and metabolic syndrome-associated disease development-an important question but only part of the answer? Alimentary pharmacology & therapeutics 56 (10) (2022)
Charlotte Lloyd, Jessica Leighton, Lin Lee Wong, Anna Goulding, Ann Brownlee, Penney Gray, Emma Culver, Neil Halliday, Doug Thorburn, Michael A Heneghan, David E J Jones, Catherine Exley, Jessica Katharine Dyson
Patient Priorities in Autoimmune Hepatitis: The Need for Better Treatments, More Education and Challenging Stigma. Digestive diseases and sciences (2022)
Neil Halliday, Jessica Katharine Dyson, Douglas Thorburn, Ansgar W Lohse, Michael A Heneghan
Review article: experimental therapies in autoimmune hepatitis. Alimentary pharmacology & therapeutics 52 (7) (2020)
Jessica Katharine Dyson, Eleonora De Martin, Georgios N Dalekos, Joost P H Drenth, Johannes Herkel, Stefan G Hubscher, Deirdre Kelly, Marco Lenzi, Piotr Milkiewicz, Ye H Oo, Michael A Heneghan, Ansgar W Lohse, null null
Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop. Alimentary pharmacology & therapeutics 49 (5) (2019)
Jessica Katharine Dyson, Lin Lee Wong, Theophile Bigirumurame, Gideon M Hirschfield, Stuart Kendrick, Ye H Oo, Ansgar W Lohse, Michael A Heneghan, David E J Jones, null null
Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. Alimentary pharmacology & therapeutics 48 (9) (2018)